AstraZeneca plc buy ValueFreak
Start price
28.12.20
/
40%
€82.10
Target price
€95.00
Performance (%)
1.94%
End price
11.01.21
€83.69
Summary
This prediction ended on 11.01.21 with a price of €83.69. With a performance of 1.94%, the BUY prediction by ValueFreak for AstraZeneca plc closed with a slight gain. ValueFreak has a follow-up prediction for AstraZeneca plc where he still thinks AstraZeneca plc is a Buy. ValueFreak has 40% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| AstraZeneca plc | 8.995% | 8.995% | 4.792% | 61.475% |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% | 16.867% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% | 45.898% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% | 2.760% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% | 42.955% |
According to ValueFreak what are the pros and cons of AstraZeneca plc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
positive Cash Flow expected
Higher EBIT margin than peer group
Fair valuation
Top Rating
Strong uniques
High Investments for future growth
Valuable balance sheet
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Very capable Management
Very good company culture
Leading role in innovation
Very differentiated customer and product portfolio
Growths much faster than the competition
Sustainability is important
Management is a major shareholder
Small Risks for its business
Very small cyclical dependencies
Well known brand
Very Future proof/growth oriented business model
Market Leader or Top 3
Cons
Low dividend yield expected
Comments by ValueFreak for this prediction
In the thread AstraZeneca plc diskutieren
Zweites Long für CTM (zusätzlich zu ADR)
In the thread Trading AstraZeneca plc
Current prediction by ValueFreak for AstraZeneca plc
AstraZeneca plc
Start price
Target price
Perf. (%)
€124.30
11.11.22
11.11.22
€165.00
08.09.26
08.09.26
18.46%
10:07
10:07
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
positive Cash Flow expected
